Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Necrotizing Enterocolitis Market Grown from 2024 to 2025?

In recent times, there has been a significant expansion in the necrotizing enterocolitis market. The market’s size, which is poised to surge from $4.83 billion in 2024 to $5.16 billion in 2025, will do so at a compound annual growth rate (CAGR) of 6.8%. Factors contributing to the growth throughout the historic period include a rising incidence of necrotizing enterocolitis, population growth, an increase in per capita income, heightened government funding, and a surge in premature birth rates.

What Growth Rate Is Anticipated for the Necrotizing Enterocolitis Market in the Coming Years?

Anticipations are high for substantial growth in the necrotizing enterocolitis market in the coming years, with its size projected to reach $6.62 billion by 2029. This increase, expected at a compound annual growth rate (CAGR) of 6.4%, is due to various factors including rising healthcare costs, occurrence and incidence rates of ulcerative colitis (UC), and elevated gastrointestinal disorders. The surge in elderly and obese population also contributes to this growth, coupled with the upswing in the geriatric population. Key trends expected within this forecast period include progress in biomarker studies for early detection of NEC, breakthroughs in non-invasive diagnostic methods, the utilization of cutting-edge monitoring systems, updates in surgical methodologies, and the evolution of aimed therapies.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22068&type=smp

Who Are the Leading Companies in the Necrotizing Enterocolitis Market?

Major companies operating in the necrotizing enterocolitis market are Abbott Laboratories, Astellas Pharma Inc., Mayo Foundation for Medical Education and Research, Cleveland Clinic, Boston Children’s Hospital, Hollister Incorporated, UPMC Children’s Hospital of Pittsburgh, Prolacta Bioscience Inc., Evolve BioSystems, Sigma-Tau Pharmaceuticals, Mead Johnson & Company LLC, Liminal BioSciences Inc., Noveome Biotherapeutics Inc., Infant Bacterial Therapeutics, Prometic Life Sciences Inc., Nexilico, Siolta Therapeutics, ProThera Biologics Inc., Plakous Therapeutics Inc., Chosen Diagnostics Inc.

What Are the Key Drivers of the Necrotizing Enterocolitis Market?

The surge in premature births is anticipated to boost the progress of the necrotizing enterocolitis market in the future. Premature births, often termed preterm births, pertain to delivering a baby prior to the completion of a standard 40-week gestation period, specifically before the 37th week. Factors contributing to this surge include maternal health complications such as high blood pressure, diabetes, infections that escalate the potential for preterm labor, along with lifestyle influences like smoking, substance abuse, and inadequate nutrition, which elevate the odds of premature births. The escalation in preterm births leads to an increased number of necrotizing enterocolitis (NEC) cases because premature babies possess underdeveloped gastrointestinal systems, which enhances their vulnerability to inflammation and infection. For example, per data released by the Centers for Disease Control and Prevention, a government agency in the US, in January 2024, 8.67% of total annual births in the United States are premature. Consequently, the escalating number of premature births is fueling the advancement of the necrotizing enterocolitis market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=22068&type=smp

What Are the Key Market Segments in the Necrotizing Enterocolitis Industry?

The necrotizing enterocolitis market covered in this report is segmented –

1) By Treatment: Total Parenteral Nutrition (TPN), Gastrointestinal Decompression, Antimicrobial Therapy, Antifungal Treatment, Paracentesis, Other Treatments

2) By Diagnosis: Laboratory Tests, Imaging Techniques

3) By Stage: Stage I (Suspected Necrotizing Enterocolitis), Stage II (Definite Necrotizing Enterocolitis), Stage III (Advanced Necrotizing Enterocolitis)

4) By Distribution Channel: Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels

5) By End-User: Hospitals, Neonatal Intensive Care Units (NICUs), Specialty Clinics

Subsegments:

1) By Total Parenteral Nutrition (TPN): Standard TPN Formulations, Customized Or Individualized TPN Solutions, Lipid Emulsions for TPN, Protein And Amino Acid Supplements In TPN, Micronutrient And Electrolyte-Enhanced TPN

2) By Gastrointestinal Decompression: Nasogastric Tube (NG Tube) Decompression, Orogastric Tube Decompression, Surgical Gastrostomy for Decompression, Non-Surgical Decompression Techniques

3) By Antimicrobial Therapy: Broad-Spectrum Antibiotics, Gram-Positive Coverage Antibiotics, Gram-Negative Coverage Antibiotics, Combination Antibiotic Therapy, Prophylactic Antibiotic Strategies For High-Risk Neonates

4) By Antifungal Treatment: Systemic Antifungal Therapy, Prophylactic Antifungal Therapy For Preterm Infants, Combination Antifungal And Antibiotic Therapy For Severe NEC

5) By Paracentesis: Diagnostic Paracentesis, Therapeutic Paracentesis, Guided Paracentesis using Ultrasound Or Radiological Techniques

6) By Other Treatments: Probiotics And Prebiotics for NEC Prevention, Surgical Interventions, Stem Cell Therapy And Regenerative Medicine Approaches, Immunomodulatory Therapies, Supportive Care

What Are the Latest Trends in the Necrotizing Enterocolitis Market?

Leading corporations in the necrotizing enterocolitis market are emphasizing the creation of inventive product solutions, including cell-free sterile biologic solutions, to meet the crucial need for capable treatments and enhance outcomes for premature infants. A cell-free sterile biologic solution constitutes a sterilized, purified fluid housing bioactive elements such as proteins, growth hormones, and cytokines extracted from cultured cells, but void of any intact cells. This solution is structured to stimulate healing and mitigate inflammation. For example, Noveome Biotherapeutics, Inc., an American biopharmaceutical firm, received approval from the U.S. Food and Drug Administration (FDA) in December 2023 to commence its Phase 1-2 clinical trial for ST266, an innovative biologic product focused on treating necrotizing enterocolitis (NEC) in newborns. This represents a significant leap as ST266 is projected to be the pioneer significant therapeutic progression for NEC in more than 30 years, addressing a fundamental medical requirement considering the disease’s high rates of illness and death among at-risk groups.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/necrotizing-enterocolitis-global-market-report

What Are the Key Regional Markets in the Necrotizing Enterocolitis Industry?

North America was the largest region in the necrotizing enterocolitis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the necrotizing enterocolitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=22068

This Report Delivers Insight On:

1. How big is the necrotizing enterocolitis market, and how is it changing globally?

2. Who are the major companies in the necrotizing enterocolitis market, and how are they performing?

3. What are the key opportunities and risks in the necrotizing enterocolitis market right now?

4. Which products or customer segments are growing the most in the necrotizing enterocolitis market?

5. What factors are helping or slowing down the growth of the necrotizing enterocolitis market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model